A
163.32
-0.84 (-0.51%)
| Penutupan Terdahulu | 164.16 |
| Buka | 164.27 |
| Jumlah Dagangan | 331,905 |
| Purata Dagangan (3B) | 460,931 |
| Modal Pasaran | 9,879,913,472 |
| Harga / Jualan (P/S) | 19.89 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 1 Sep 2025 - 5 Sep 2025 |
| Margin Keuntungan | -92.67% |
| Margin Operasi (TTM) | -103.23% |
| EPS Cair (TTM) | -6.79 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 5.30% |
| Nisbah Semasa (MRQ) | 1.04 |
| Aliran Tunai Operasi (OCF TTM) | -218.93 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -133.44 M |
| Pulangan Atas Aset (ROA TTM) | -22.39% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Menurun |
| Biotechnology (Global) | Bercampur | Menurun | |
| Stok | Ascendis Pharma A/S | Menaik | Menaik |
AISkor Stockmoo
1.6
| Konsensus Penganalisis | 5.0 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | 1.0 |
| Purata Bergerak Teknikal | -1.5 |
| Osilator Teknikal | 2.0 |
| Purata | 1.63 |
|
Ascendis Pharma AS is a biopharmaceutical company that applies its TransCon technology platform to make a meaningful difference for patients. The firm's product pipeline includes Endocrinology and Oncology which includes TransCon PTH, TransCon CNP, and others. It operates in North America, Europe, and Rest of the world and derives the majority of its revenue from North America. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 0.78% |
| % Dimiliki oleh Institusi | 113.63% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 307.00 (UBS, 87.98%) | Beli |
| Median | 250.00 (53.07%) | |
| Rendah | 203.00 (Cantor Fitzgerald, 24.30%) | Beli |
| Purata | 249.36 (52.68%) | |
| Jumlah | 11 Beli | |
| Harga Purata @ Panggilan | 183.81 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Cantor Fitzgerald | 08 Aug 2025 | 203.00 (24.30%) | Beli | 191.49 |
| Citigroup | 08 Aug 2025 | 290.00 (77.57%) | Beli | 191.49 |
| 11 Jul 2025 | 243.00 (48.79%) | Beli | 174.96 | |
| RBC Capital | 08 Aug 2025 | 230.00 (40.83%) | Beli | 191.49 |
| Stifel | 08 Aug 2025 | 254.00 (55.52%) | Beli | 191.49 |
| UBS | 08 Aug 2025 | 307.00 (87.97%) | Beli | 191.49 |
| Wedbush | 08 Aug 2025 | 220.00 (34.70%) | Beli | 191.49 |
| Wells Fargo | 08 Aug 2025 | 295.00 (80.63%) | Beli | 191.49 |
| JP Morgan | 29 Jul 2025 | 254.00 (55.52%) | Beli | 163.32 |
| Morgan Stanley | 03 Jul 2025 | 250.00 (53.07%) | Beli | 174.18 |
| Oppenheimer | 13 Jun 2025 | 224.00 (37.15%) | Beli | 170.80 |
| B of A Securities | 09 Jun 2025 | 216.00 (32.26%) | Beli | 173.15 |
| 03 Jun 2025 | 201.00 (23.07%) | Beli | 174.40 | |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |